Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA issues H1N1 warning letters

This article was originally published in The Tan Sheet

Executive Summary

FDA warns Cashburners, the website manager and host site for Flu Defence dietary supplement - sold on fludefence.org, fludefence.net and swinefludefence.org - to stop marketing the supplement, because it is unapproved by FDA to diagnose, mitigate, prevent, treat or cure H1N1. In warning letters sent June 2 to the domain protector and website marketer located in New Zealand, the Netherlands and Westchester, Calif., the agency takes issue with claims including "[E]xhibits strong antiviral action against influenza A & 8, birdflu ... swine flu." FDA teamed with the Federal Trade Commission and foreign governments to root out improper claims regarding products that treat or prevent H1N1 flu (1"The Tan Sheet" Oct. 19, 2009). FDA also warned Nature's Gift in a letter posted June 11 to discontinue claims on its blog that Flu Foil Synergy, Flu Foil Synergy with Inhaler, Ravensara and Ravintsara could diagnose, mitigate, prevent, treat or cure H1N1 because the products are unapproved

You may also be interested in...



FTC Stakes New Territory, Joins FDA In Warning On H1N1 Claims

A warning letter sent jointly by FDA and the Federal Trade Commission takes a double-pronged approach toward cracking down on a supplement marketer's claims regarding the H1N1 flu virus

Pink Sheet Podcast: COVID Vaccine In Adolescents, CMS Drug Pricing Moves, Standard Care In Clinical Trials

Pink Sheet reporters and editors discuss the US FDA decision to lower the eligibility age for the Pfizer/BioNTech COVID-19 vaccine, CMS drug pricing project plans, and mid-stream standard of care changes in drug development.

Keeping Track: US FDA Approves Heron’s Zynrelef In Post-Op Pain; Amgen/AZ Submit Tezepelumab For Severe Asthma

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Topics

UsernamePublicRestriction

Register

PS104199

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel